1. Home
  2. REPL
  3. REPL News

Latest Replimune Group Inc. (REPL) News on November 7, 2025

REPL

GlobeNewswire

a day ago

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

REPL

MT Newswires

4 days ago

BMO Capital Upgrades Replimune Group to Market Perform From Underperform, Adjusts Price Target to $11 From $2

Replimune Group (REPL) Is Up 86.2% After FDA Accepts Resubmitted RP1 Application for Advanced Melanoma—Has The Bull Case Changed?
REPL

Simply Wall St.

16 days ago

Replimune Group (REPL) Is Up 86.2% After FDA Accepts Resubmitted RP1 Application for Advanced Melanoma—Has The Bull Case Changed?

REPL

MT Newswires

17 days ago

Piper Sandler Upgrades Replimune Group to Overweight From Neutral, Adjusts Price Target to $13 From $8

A Look at Replimune Group’s (REPL) Valuation Following Promising IGNYTE Phase 2 Melanoma Trial Results
REPL

Simply Wall St.

17 days ago

A Look at Replimune Group’s (REPL) Valuation Following Promising IGNYTE Phase 2 Melanoma Trial Results

Why Replimune Stock Was Soaring Today
REPL

Motley Fool

18 days ago

Why Replimune Stock Was Soaring Today

REPL

MT Newswires

18 days ago

JPMorgan Upgrades Replimune Group to Neutral From Underweight, $11 Price Target

REPL

MT Newswires

18 days ago

Top Midday Gainers

REPL

MT Newswires

18 days ago

Wall Street Set to Open Higher Monday as Investors Look Ahead to a Week of Earnings Reports

REPL

MT Newswires

18 days ago

Wedbush Upgrades Replimune Group to Outperform From Neutral, Adjusts Price Target to $18 From $4

REPL

MT Newswires

18 days ago

Investors Look Ahead to Key Earnings Reports as US Futures Rise Monday Pre-Bell

REPL

GlobeNewswire

4 months ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REPL

MT Newswires

5 months ago

Cantor Fitzgerald Initiates Replimune Group at Overweight

REPL

GlobeNewswire

5 months ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REPL

GlobeNewswire

5 months ago

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

REPL

GlobeNewswire

5 months ago

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...
REPL

GuruFocus.com

5 months ago

Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...

REPL

Thomson Reuters StreetEvents

5 months ago

Q4 2025 Replimune Group Inc Earnings Call

REPL

GlobeNewswire

6 months ago

Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

REPL

GlobeNewswire

6 months ago

Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day

REPL

GlobeNewswire

6 months ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REPL

GlobeNewswire

7 months ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REPL

GlobeNewswire

8 months ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REPL

MT Newswires

9 months ago

Wedbush Raises Replimune Group's Price Target to $19 From $16, Keeps Outperform Rating

REPL

GlobeNewswire

9 months ago

Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

REPL

GlobeNewswire

9 months ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Replimune price target raised to $21 from $17 at H.C. Wainwright
REPL

TipRanks

9 months ago

Replimune price target raised to $21 from $17 at H.C. Wainwright

REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA
REPL

Zacks

10 months ago

REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA

Replimune Stock Soars 16% on FDA Priority Review for Advanced Melanoma Therapy
REPL

GuruFocus.com

10 months ago

Replimune Stock Soars 16% on FDA Priority Review for Advanced Melanoma Therapy

REPL

MT Newswires

10 months ago

Replimune Group Says Lead Therapy RP1 Gains US FDA's Priority Review

REPL

GlobeNewswire

10 months ago

Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma

REPL

GlobeNewswire

10 months ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REPL

GlobeNewswire

10 months ago

Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials

REPL

GlobeNewswire

10 months ago

Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference

REPL

MT Newswires

a year ago

Replimune Prices Upsized $140 Million Offerings

REPL

GlobeNewswire

a year ago

Replimune Announces Pricing of Upsized Public Offering

REPL

MT Newswires

a year ago

Replimune Plans $125 Million Stock Sale, Net Proceeds to Fund Prospective Skin Cancer Treatment

REPL

GlobeNewswire

a year ago

Replimune Announces Proposed Public Offering

S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results
REPL

Benzinga

a year ago

S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results

Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug
REPL

Zacks

a year ago

Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug

REPL

Investing.com

a year ago

Replimune's stock surges 19% after-hours on FDA BLA submission

REPL

MT Newswires

a year ago

Replimune Files RP1 Biologics License Application With US FDA; Gets Breakthrough Therapy Designation for RP1

REPL

GlobeNewswire

a year ago

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

REPL

GlobeNewswire

a year ago

Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

REPL

GlobeNewswire

a year ago

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

REPL

GlobeNewswire

a year ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REPL

GlobeNewswire

a year ago

Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

REPL

GlobeNewswire

a year ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings
REPL

GuruFocus.com

a year ago

Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 48% Below Their Intrinsic Value Estimate
REPL

Simply Wall St.

a year ago

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 48% Below Their Intrinsic Value Estimate

REPL

GlobeNewswire

a year ago

Replimune to Present at Two Upcoming Investor Conferences

REPL

MT Newswires

a year ago

Sector Update: Health Care Stocks Flat to Higher Premarket Monday

REPL

MT Newswires

a year ago

Replimune Group Says Potential Melanoma Treatment Study Yielded Positive Results

REPL

GlobeNewswire

a year ago

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024

REPL

MT Newswires

a year ago

Replimune Plans to Submit Biologics License Application for RP1 in H2 After 'Successful' Pre-BLA Meeting

REPL

GlobeNewswire

a year ago

Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024

REPL

GlobeNewswire

a year ago

Stockholders Vote to Elect Madhavan Balachandran to Board of Directors

REPL

GlobeNewswire

a year ago

Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024

Replimune kickstarts Phase III melanoma trial studying RP1 immunotherapy
REPL

Pharmaceutical Technology

a year ago

Replimune kickstarts Phase III melanoma trial studying RP1 immunotherapy

REPL

GlobeNewswire

a year ago

Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

REPL

GlobeNewswire

a year ago

Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update

REPL

GlobeNewswire

a year ago

Replimune to Present at Two Upcoming Investor Conferences

REPL

MT Newswires

a year ago

Replimune Group Signs $100 Million PIPE Deal with Institutional Investors

REPL

GlobeNewswire

a year ago

Replimune Announces $100 Million Private Placement Financing

See's Candies® Launches New Scotchmallow® Littles
REPL

PR Newswire

a year ago

See's Candies® Launches New Scotchmallow® Littles

Stock futures slip as markets digest hot jobs data
REPL

Yahoo Finance Video

a year ago

Stock futures slip as markets digest hot jobs data

IBHS honors resilient construction trailblazers
REPL

PR Newswire

a year ago

IBHS honors resilient construction trailblazers

SOUTHWEST AIRLINES RANKED TOP AIRLINE ON FORBES AMERICA'S BEST EMPLOYERS FOR VETERANS LIST
REPL

PR Newswire

a year ago

SOUTHWEST AIRLINES RANKED TOP AIRLINE ON FORBES AMERICA'S BEST EMPLOYERS FOR VETERANS LIST

Lyft Stock Rides High On Bullish Double-Upgrade After Company Offers New Growth Targets
REPL

Investor's Business Daily

a year ago

Lyft Stock Rides High On Bullish Double-Upgrade After Company Offers New Growth Targets

REPL

Benzinga

a year ago

Bill Gates Could Be The World's First Trillionaire If He Had 'Diamond Handed' His Microsoft Shares — He'd Be Sitting On $1.47 Trillion Today

Argus Research Updated Equity Report Coverage On Tego Cyber Inc.
REPL

ACCESSWIRE

a year ago

Argus Research Updated Equity Report Coverage On Tego Cyber Inc.

Kohler Mira Ltd. Celebrates Mental Health Awareness Week in the UK: Promoting Wellbeing and Sharing Healthy Habits
REPL

ACCESSWIRE

a year ago

Kohler Mira Ltd. Celebrates Mental Health Awareness Week in the UK: Promoting Wellbeing and Sharing Healthy Habits

Replimune (REPL) Gains on Positive Data From Melanoma Study
REPL

Zacks

a year ago

Replimune (REPL) Gains on Positive Data From Melanoma Study

REPL

MT Newswires

a year ago

HC Wainwright Adjusts Price Target on Replimune to $17 From $12, Maintains Buy Rating

REPL

GlobeNewswire

a year ago

Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

REPL

MT Newswires

a year ago

Sector Update: Health Care Stocks Higher in Late Afternoon Trading

REPL

MT Newswires

a year ago

Replimune Shares Rise as Study Data on Melanoma Treatment Improves

Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
REPL

Benzinga

a year ago

Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?

REPL

GlobeNewswire

a year ago

Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

REPL

GlobeNewswire

a year ago

Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

REPL

GlobeNewswire

a year ago

Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

REPL

GlobeNewswire

a year ago

Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update

REPL

GlobeNewswire

2 years ago

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting

REPL

GlobeNewswire

2 years ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REPL

GlobeNewswire

2 years ago

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%
REPL

Zacks

2 years ago

How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%

What Makes Replimune Group, Inc. (REPL) a New Buy Stock
REPL

Zacks

2 years ago

What Makes Replimune Group, Inc. (REPL) a New Buy Stock

REPL

GlobeNewswire

2 years ago

Replimune to Present at the American Association for Cancer Research Annual Meeting 2024

REPL

GlobeNewswire

2 years ago

Replimune to Present at Three Upcoming Investor Conferences

12 Best Medical Stocks to Buy Under $10
REPL

Insider Monkey

2 years ago

12 Best Medical Stocks to Buy Under $10

Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High?
REPL

Zacks

2 years ago

Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High?

Replimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runway
REPL

GuruFocus.com

2 years ago

Replimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runway

REPL

GlobeNewswire

2 years ago

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

REPL

Business Wire

2 years ago

B&G Foods Releases Inaugural Corporate Social Responsibility Report

Those who invested in Veeco Instruments (NASDAQ:VECO) five years ago are up 221%
REPL

Simply Wall St.

2 years ago

Those who invested in Veeco Instruments (NASDAQ:VECO) five years ago are up 221%

Atlanticus Prices $50 Million Offering of Senior Notes
REPL

GlobeNewswire

2 years ago

Atlanticus Prices $50 Million Offering of Senior Notes

Veeco Announces Date for Fourth Quarter and Full-Year 2023 Financial Results and Conference Call
REPL

GlobeNewswire

2 years ago

Veeco Announces Date for Fourth Quarter and Full-Year 2023 Financial Results and Conference Call

Washington Trust Bancorp (WASH) Surpasses Q4 Earnings Estimates
REPL

Zacks

2 years ago

Washington Trust Bancorp (WASH) Surpasses Q4 Earnings Estimates

Covenant Logistics Group Inc. Reports Fourth Quarter Earnings Amid Market Challenges
REPL

GuruFocus.com

2 years ago

Covenant Logistics Group Inc. Reports Fourth Quarter Earnings Amid Market Challenges

Business First Bancshares Inc Reports Mixed Results for FY 2023 and Q4
REPL

GuruFocus.com

2 years ago

Business First Bancshares Inc Reports Mixed Results for FY 2023 and Q4

Share on Social Networks: